A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 175-182

  Meseck, Marcia ^a   Huang, Tiangui ^a   Ma, Ge ^a   Wang, George ^a   Chen, Shu Hsia ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

4 1BBL; cancer; immunotherapy; T cell activation

Indexed keywords

ANTINEOPLASTIC AGENT; CD137 ANTIGEN; GLUTAMATE AMMONIA LIGASE; HUMAN IMMUNOGLOBULIN; HUMAN IMMUNOGLOBULIN RECOMBINANT HUMAN 4 1BB LIGAND FUSION PROTEIN; METHIONINE SULFOXIMINE; PROTEIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CHINESE HAMSTER; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG PROTEIN BINDING; HAPLORHINI; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; OVARY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

EID: 85027954154     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318207ed14     Document Type: Article

References (24)

1. Driessens G, Kline J, Gajewski v. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229:126-144.
2. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol. 1998;10:481-489. (Pubitemid 28564377)
3. Kwon B, Moon CH, Kang S, et al. 4-1BB: still in the midst of darkness. Mol Cells. 2000;10:119-126.
4. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008;222:357-368. (Pubitemid 351430366)
5. Pollok KE, Kim YJ, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993; 150:771-781. (Pubitemid 23133657)
6. Melero I, Johnston JV, Shufford WW, et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190:167-172. (Pubitemid 29011104)
7. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol. 2002;14:275-286. (Pubitemid 34213639)
8. Wilcox RA, Chapoval AI, Gorski KS, et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol. 2002;168:4262-4267. (Pubitemid 34441322)
9. Wang C, Lin GHY, McPherson AJ, et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev. 2009;229:192-215.
10. Kim YJ, Broxmeyer HE. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells. J Hematother Stem Cell Res. 2001;10:441-449. (Pubitemid 32756184)
11. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685. (Pubitemid 27264981)
12. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109:651-659. (Pubitemid 34204844)
13. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst. 2000;92:931-936. (Pubitemid 30429194)
14. Xu DP, Sauter BV, Huang TG, et al. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther. 2005; 12:1526-1533. (Pubitemid 41508678)
15. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105:9-19. (Pubitemid 34128035)
16. Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27:767-771.
17. Aalberse RC, Stapel SO, Schuurman J, et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39:469-477.
18. De la Cruz Edmonds MC, Tellers M, Chan C, et al. Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol Biotechnol. 2006;34:179-190. (Pubitemid 46030391)
19. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001;167:1313-1324. (Pubitemid 32703127)
20. Pullen SS, Labadia ME, Ingraham RH, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry. 1999;38:10168-10177.
21. Rabu C, Quemener A, Jacques Y, et al. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem. 2005;280:41472-41481. (Pubitemid 41832207)
22. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178:661-667. (Pubitemid 23218215)
23. Bebbington CR, Renner G, Thomson S, et al. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y). 1992;10:169-175.
24. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393-1398. (Pubitemid 39482858)